Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM8002 plus nab-paclitaxel as first-line therapy for advanced triple-negative breast cancer
ChiCTR2200060400Phase 2Not yet recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Mar 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pumitamig in triple-negative breast cancer (TNBC), sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Objective response rate and Incidence and severity of treatment-related adverse events. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
pumitamig
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2200060400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200060400.